Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results

Changes in tumor perfusion detected with dynamic contrast-enhanced US as early as 3 days after initiation of bevacizumab therapy may be predictive of tumor response, progression-free survival, and overall survival in patients with hepatocellular carcinoma.